Medica Venture Partners

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

Impella CardioSystems AG, based in Aachen, Germany, develops, manufactures and markets minimally invasive cardiovascular support systems for numerous indications in the fields of cardiology and coronary surgery. The company's technology is protected by more than 30 European and international patents, and currently employees 50 individuals. For the last 2 years Impella has been affiliated with and assisted by Accelerated Technologies, Inc (ATI), a medical device accelerator located in Hackensack, NJ.

Orex Computed Radiography manufactures computerized radiography solutions. The company’s products includes Kodak Point-of-Care CR120, CR140, and CR260 that enables medical practitioners to acquire patient digital x-ray images from around the world. KODAK Point-of-Care CR-ITX 560 is a solution system that brings digital x-ray imaging directly to the patient. KODAK CR 7400 Digital Radiography is a system that delivers intraoral and extra oral images digitally. Orex Computed Radiography is an Israel-based company that was founded in 1996. The company was acquired by Kodak on January 19, 2005.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

Remon Medical Technologies is a development-stage company focused on communication technology for medical device applications. It offers RemonCHF, a device that monitors the hemodynamic status of patients with congestive heart failure; and RemonAAA, a device that monitors pressure following an endograft procedure in AAA patients. The company is based in Caesarea, Israel.

InterCure Ltd. invests in the biomedical, life sciences, and biotechnology sectors in Israel and internationally. The company was formerly known as Ben Gavish Ltd. and changed its name to InterCure Ltd. in June 1997. InterCure Ltd. was founded in 1994 and is based in Hadera, Israel.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

InterCure Ltd. invests in the biomedical, life sciences, and biotechnology sectors in Israel and internationally. The company was formerly known as Ben Gavish Ltd. and changed its name to InterCure Ltd. in June 1997. InterCure Ltd. was founded in 1994 and is based in Hadera, Israel.

FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.